Ongoing trials will determine if liraglutide (41), lixisenatide (ELIXIRS trial) (42) and semaglutide (FLOW trial) (43) reduce dialysis rates and reduce worsening kidney function in people with diabetic kidney disease
HbA1c The adjusted mean HbA1c change in the semaglutide group was 3.6 mmol mol 1 (s.e
Enrolling Overweight Obesity Drug: Eloralintide Drug: Placebo A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients
GLP-1 receptor agonists mitigate neuroinflammation, they mitigate oxidative stress, [and] they mitigate a number of things which occur systemically but also in the brain, Nigel Greig, principal investigator at the National Institute on Aging, told ABC News
10.1021/pr4010986 8 ChenH
Alpha lipoic acid can affect insulin signaling and glucose metabolism, and potentially impact other cell signaling molecules involved in hepatic function and vasodilation